China News Service, September 14 (Reporter Chen Jing) Lung cancer is currently the most common malignant tumor with the highest fatality rate in the world.
Non-small cell lung cancer (NSCLC) accounts for more than 80% of lung cancer cases.
The "Chinese Expert Consensus on Anti-angiogenic Drugs for Advanced Non-small Cell Lung Cancer (2020 Edition)" (hereinafter referred to as "Consensus") was officially released in Shanghai on the 14th, and the anti-angiogenic drug combined immunization program became the first line of advanced non-small cell lung cancer (NSCLC) Treatment options.
The "Consensus" was written by the Chinese Society of Clinical Oncology (CSCO) Vascular Targeted Therapy Expert Committee and Non-Small Cell Lung Cancer Expert Committee.
It is reported that due to the high invasiveness of NSCLC and the lack of effective early screening programs, most patients in China are already at an advanced stage when they are diagnosed.
Professor Han Baohui, head of the "Consensus" editorial board and Shanghai Jiaotong University Thoracic Hospital, said: "The level of clinical tumor treatment in China varies greatly. The Chinese Society of Clinical Oncology has been committed to improving the overall level of clinical tumor treatment in China. "Consensus" The formulation of the NSCLC has an important guiding role in the clinical practice of advanced NSCLC, and will improve the standardization of treatment by Chinese primary hospitals and doctors, and promote the popularization of anti-angiogenic drugs.” Professor Zhou Caicun of Shanghai Pulmonary Hospital affiliated to Tongji University pointed out that the "Consensus" combines more Based on multiple meta-analysis, real world data and clinical practice experience.
As one of the initiators of the "Consensus", Professor Han Baohui pointed out: "Immunotherapy is currently the focus of global cancer treatment. The availability of immunotherapeutics in China is steadily improving. The "Consensus" introduced an anti-angiogenesis combined immunotherapy program for the first time. Among them, it will further extend the survival period of patients." Professor Chu Tianqing from the Thoracic Hospital of Shanghai Jiaotong University revealed that as more targeted therapies continue to emerge, the "Consensus" also emphasizes that anti-angiogenesis drugs combined with targeted drugs can make relevant Patients benefit.
Related treatment options will delay the resistance of targeted drugs.
(Finish)